Coadministration resulted in high rate of discontinuation due to adverse events (nausea, headache, vomiting, dizziness, dyspepsia, fatigue) with 36% of patients discontinuing treatment.
Source: NLP:varenicline
Brand names: Varenicline
Route: Oral
Contraindications
4 CONTRAINDICATIONS Varenicline tablets are contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to varenicline. History of serious hypersensitivity or skin reactions to varenicline ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Available data have not suggested an increased risk for major birth defects following exposure to varenicline in pregnancy, compared with women who smoke [see Data]. Smoking during pregnancy is associated with maternal, fetal, and neonatal risks (see Clinical Considerations). In animal studies, varenicline did not result in major malformations but caused decreased fetal weights in rabbits when dosed during organogenesis at exposures equivalent to 50 times the exposure at the maximum recommended human dose (MRHD). Additionally, administration of varenicline to pregnant rats during organogenesis through lactation produced developmental toxicity in offspring at maternal exposures equivalent to 36 times human exposure at the MRHD [see Data] . The estimated background risk of oral clefts is increased by approximately 30% in infants of women who smoke during pregnancy, compared to pregnant women who do not smoke. The background risk of other major birth defects and miscarriage for the indicated population are unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Smoking during pregnancy causes increased risks of orofacial clefts, premature rupture of membranes, placenta previa, placental abruption, ectopic pregnancy, fetal growth restriction and low birth weight, stillbirth, preterm delivery and shortened gestation, neonatal death, sudden infant death syndrome and reduction of lung function in infants. It is not known whether quitting smoking with varenicline tablets during pregnancy reduces these risks. Data Human Data A population-based observational cohort study using the national registers of Denmark and Sweden compared pregnancy and birth outcomes among women exposed to varenicline (N=335, includes 317 first trimester exposed) with wome
5 interactions on record
Coadministration resulted in high rate of discontinuation due to adverse events (nausea, headache, vomiting, dizziness, dyspepsia, fatigue) with 36% of patients discontinuing treatment.
Source: NLP:varenicline
Smoking cessation with varenicline may alter insulin pharmacokinetics or pharmacodynamics, necessitating dose adjustment.
Source: NLP:varenicline
Smoking cessation with varenicline may alter theophylline pharmacokinetics or pharmacodynamics, necessitating dose adjustment.
Source: NLP:varenicline
Smoking cessation with varenicline may alter warfarin pharmacokinetics or pharmacodynamics, necessitating dose adjustment.
Source: NLP:varenicline
Varenicline did not alter bupropion steady-state pharmacokinetics, but safety of combination has not been established.
Source: NLP:varenicline